Stock Track | Biogen Plunges 5.3% Pre-Market as 2025 Profit Outlook Disappoints, Faces Stiff Competition

Stock Track

Feb 12, 2025

Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.

The company's lackluster performance is attributed to two key factors:
1. The impact of a strong U.S. dollar, which has eroded the company's overseas revenue and profit.
2. Intensifying competition for its multiple sclerosis drugs, which have faced fierce rivalry in the market.

Despite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company expects 2025 revenue to decline by a mid-single-digit percentage, excluding currency fluctuations, from 2024 levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161330115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161330115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161330115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161330115","market":"hk","top_or_hot":-1,"title":"Stock Track | Biogen Plunges 5.3% Pre-Market as 2025 Profit Outlook Disappoints, Faces Stiff Competition","media":"Stock Track","content":"<p>Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.</p>\n\n<p>The company's lackluster performance is attributed to two key factors:\n<br>\n1. The impact of a strong U.S. dollar, which has eroded the company's overseas revenue and profit.\n<br>\n2. Intensifying competition for its multiple sclerosis drugs, which have faced fierce rivalry in the market.</p>\n\n<p>Despite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company expects 2025 revenue to decline by a mid-single-digit percentage, excluding currency fluctuations, from 2024 levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Biogen Plunges 5.3% Pre-Market as 2025 Profit Outlook Disappoints, Faces Stiff Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Biogen Plunges 5.3% Pre-Market as 2025 Profit Outlook Disappoints, Faces Stiff Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-12 19:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.</p>\n\n<p>The company's lackluster performance is attributed to two key factors:\n<br>\n1. The impact of a strong U.S. dollar, which has eroded the company's overseas revenue and profit.\n<br>\n2. Intensifying competition for its multiple sclerosis drugs, which have faced fierce rivalry in the market.</p>\n\n<p>Despite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company expects 2025 revenue to decline by a mid-single-digit percentage, excluding currency fluctuations, from 2024 levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1161330115","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161330115","pubTimestamp":1739361152,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.The company's lackluster performance is attributed to two key factors:. Despite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"由于2025年利润前景令人失望，面临激烈竞争，Biogen股价盘前暴跌5.3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen Inc.'s stock took a hit in the pre-market trading session on Wednesday, plummeting 5.3% as the biopharmaceutical company forecasted 2025 profit below Wall Street expectations.\nThe company's lackluster performance is attributed to two key factors:\n\n1. The impact of a strong U.S. dollar, which has eroded the company's overseas revenue and profit.\n\n2. Intensifying competition for its multiple sclerosis drugs, which have faced fierce rivalry in the market.\nDespite efforts by the new CEO, Christopher Viehbacher, to streamline operations and pursue acquisitions, such as the $6.5 billion takeover of Reata Pharmaceuticals in 2023, concerns remain about Biogen's ability to sustain growth. The company expects 2025 revenue to decline by a mid-single-digit percentage, excluding currency fluctuations, from 2024 levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}